1-丙基哌嗪盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-丙基哌嗪盐酸盐
• 英文名称: 1-propylpiperazine dihydrochloride
• 英文别名: N-propylpiperazine dihydrochloride；1-Propyl-piperazin; Dihydrochlorid；1-n-propylpiperazine dihydrochloride；hydron;1-propylpiperazine;chloride
• 化学式: C₇H₁₆N₂*2ClH
• 分子量: 201.139
• InChiKey: QFCLTBGHRZKNGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [CB[6]*PP*Na](3+) 、 1-丙基哌嗪盐酸盐 在 sodium chloride 作用下， 以 水 为溶剂， 生成 [CB[6]*2(PP)](4+)
  参考文献：
  名称：

  N-烷基和N，N'-二烷基哌嗪与葫芦[6]尿素在水溶液和固态中的超分子络合

  摘要：

  水种子：葫芦[6]尿素（CB [6]）与N-烷基和N，N'-二烷基哌嗪的络合物化学计量/组成和低聚度（低聚超分子复合物形成）在水溶液中通过等温法研究滴定量热法（ITC），ESI-MS，NMR和光散射测量。

  DOI：

  10.1002/chem.200800398

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• [EN] SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] BENZIMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：BIAL BIOTECH INVEST INC

  公开号：WO2021055591A1

  公开（公告）日：2021-03-25

  The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

  这项发明提供了替代苯并咪唑羧酰胺及相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗疾病的方法，例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病。
• Non-imidazole histamine H3 ligands, Part IV: SAR of 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives
  作者：Anna Frymarkiewicz、Krzysztof Walczyński

  DOI：10.1016/j.ejmech.2008.09.019

  日期：2009.4

  series of 1-[[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propyl]piperazine derivatives have been prepared and in vitro tested as H3-receptor antagonists (the electrically evoked contraction of the guinea pig jejunum). It appeared that by comparison of homologous pairs the 1-[[2-thiazol-5-yl-(2-methyl-2-phenylalkylaminoethyl)]-4-n-propyl]piperazine derivatives (4c1–4c3) have slightly higher activity than their

  已经制备了一系列的1-[[[2-噻唑-5-基-（2-氨基乙基）]-4-正丙基]哌嗪衍生物，并作为H 3受体拮抗剂进行了体外测试（电诱发的H 2-受体收缩）。豚鼠空肠）。看起来，通过同源双比较1 - [[2 -噻唑-5-基- （2-甲基-2- phenylalkylaminoethyl）〕 - 4- Ñ -丙基]哌嗪衍生物（4C1 - 4C3）具有比略微更高的活性他们的1- [2-噻唑-5-基-（2-甲基-2-烷基氨基乙基）]-4-正丙基哌嗪类似物（4b1 – 4b3）。在2-甲基烷基酰胺系列中（4a1 – 4a3）观察到较低的活性。该系列中最有效的化合物是1- [2-噻唑-5-基-（2-甲基-2-苯基丙基氨基乙基）]-4-正丙基哌嗪（4c2），pA 2  = 8.27（其烷基类似物（4b2）显示pA 2  = 7.53，相应的酰胺（4a2）显示pA 2  = 7.36）。 选择的化合物（4
• Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
  申请人：Portela & Ca., S.A.

  公开号：EP1167342A1

  公开（公告）日：2002-01-02

  New compounds of formula I are described: The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

  描述了化学式I的新化合物：这些化合物在治疗一些中枢和外周神经系统疾病中具有潜在的有价值的药理特性。
• The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs
  作者：Xin Chen、Hyunah Choo、Xi-Ping Huang、Xiaobao Yang、Orrin Stone、Bryan L. Roth、Jian Jin

  DOI：10.1021/cn500325v

  日期：2015.3.18

  Over the past decade, two independent technologies have emerged and been widely adopted by the neuroscience community for remotely controlling neuronal activity: optogenetics which utilize engineered channelrhodopsin and other opsins, and chemogenetics which utilize engineered G protein-coupled receptors (Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) and other orthologous ligand receptor pairs. Using directed molecular evolution, two types of DREADDs derived from human muscarinic acetylcholine receptors have been developed: hM3Dq which activates neuronal firing, and hM4Di which inhibits neuronal firing. Importantly, these DREADDs were not activated by the native ligand acetylcholine (ACh), but selectively activated by dozapine N-oxide (CNO), a pharmacologically inert ligand. CNO has been used extensively in rodent models to activate DREADDs, and although CNO is not subject to significant metabolic transformation in mice, a small fraction of CNO is apparently metabolized to clozapine in humans and guinea pigs, lessening the translational potential of DREADDs. To effectively translate the DREADD technology, the next generation of DREADD agonists are needed and a thorough understanding of structure activity relationships (SARs) of DREADDs is required for developing such ligands. We therefore conducted the first SAR studies of hM3Dq. We explored multiple regions of the scaffold represented by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM3Dq agonists but do not activate the native human M3 receptor (hM3). We also discovered that the approved drug perlapine is a novel hM3Dq agonist with >10 000-fold selectivity for hM3Dq over hM3.